Geode Capital Management’s Aprea Therapeutics APRE Stock Holding History
Bought
Maintained
Sold
Other funds holding APRE
ACM
Geode Capital Management's APRE Position: Q3 2026 in Review
Geode Capital Management reduced its Aprea Therapeutics (APRE) stake by 0.43% in Q3 2026, selling an estimated $232 and leaving 74,549 shares worth $55.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4179.
Geode Capital Management first reported a position in APRE in Q4 2019 and has held it in 27 quarters since. The position peaked at $4.12M in Q2 2020. 27 funds tracked by Wall St. Rank hold APRE as of Q3 2026.
- Geode Capital Management held 74,549 shares of Aprea Therapeutics worth $55.9K as of Q3 2026.
- Geode Capital Management sold 320 Aprea Therapeutics shares in Q3 2026, an estimated $232.
- Aprea Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #4179 holding.
- Geode Capital Management first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 27 quarters since.
- Geode Capital Management's Aprea Therapeutics position peaked at $4.12M in Q2 2020.
- 27 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2026.
Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.